@article {7688,
	title = {Microglia activation and interaction with neuronal cells in a biochemical model of mevalonate kinase deficiency.},
	journal = {Apoptosis},
	volume = {20},
	year = {2015},
	month = {2015 Aug},
	pages = {1048-55},
	abstract = {<p>Mevalonate kinase deficiency is a rare disease whose worst manifestation, characterised by severe neurologic impairment, is called mevalonic aciduria. The progressive neuronal loss associated to cell death can be studied in vitro with a simplified model based on a biochemical block of the mevalonate pathway and a subsequent inflammatory trigger. The aim of this study was to evaluate the effect of the mevalonate blocking on glial cells (BV-2) and the following effects on neuronal cells (SH-SY5Y) when the two populations were cultured together. To better understand the cross-talk between glial and neuronal cells, as it happens in vivo, BV-2 and SH-SY5Y were co-cultured in different experimental settings (alone, transwell, direct contact); the effect of mevalonate pathway biochemical block by Lovastatin, followed by LPS inflammatory trigger, were evaluated by analysing programmed cell death and mitochondrial membrane potential, cytokines{\textquoteright} release and cells{\textquoteright} morphology modifications. In this experimental condition, glial cells underwent an evident activation, confirmed by elevated pro-inflammatory cytokines release, typical of these disorders, and a modification in morphology. Moreover, the activation induced an increase in apoptosis. When glial cells were co-cultured with neurons, their activation caused an increase of programmed cell death also in neuronal cells, but only if the two populations were cultured in direct contact. Our findings, being aware of the limitations related to the cell models used, represent a preliminary step towards understanding the pathological and neuroinflammatory mechanisms occurring in mevalonate kinase diseases. Contact co-culture between neuronal and microglial cells seems to be a good model to study mevalonic aciduria in vitro, and to contribute to the identification of potential drugs able to block microglial activation for this orphan disease. In fact, in such a pathological condition, we demonstrated that microglial cells are activated and contribute to neuronal cell death. We can thus hypothesise that the use of microglial activation blockers could prevent this additional neuronal death.</p>},
	issn = {1573-675X},
	doi = {10.1007/s10495-015-1139-8},
	author = {Tricarico, Paola Maura and Piscianz, Elisa and Monasta, Lorenzo and Kleiner, Giulio and Crovella, Sergio and Marcuzzi, Annalisa}
}
@article {3505,
	title = {Mevalonate kinase deficiency and IBD: shared genetic background.},
	journal = {Gut},
	volume = {63},
	year = {2014},
	month = {2014 Aug},
	pages = {1367-8},
	keywords = {Genetic Predisposition to Disease, Humans, Inflammatory Bowel Diseases},
	issn = {1468-3288},
	doi = {10.1136/gutjnl-2013-306555},
	author = {Bianco, Anna Monica and Girardelli, Martina and Vozzi, Diego and Crovella, Sergio and Kleiner, Giulio and Marcuzzi, Annalisa}
}
@article {1928,
	title = {Mevalonate kinase deficiency: disclosing the role of mevalonate pathway modulation in inflammation.},
	journal = {Curr Pharm Des},
	volume = {18},
	year = {2012},
	month = {2012},
	pages = {5746-52},
	abstract = {<p>Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes. Most of these proteins belong to a few families and share the capability of sensing pathogen-associated and damageassociated molecular patterns. By interacting with each other, these proteins participate in the assembly of molecular platforms, called inflammasomes, which ultimately lead to the activation of cytokines, to the transcription of inflammatory genes or to the induction of cell apoptosis. Among hereditary periodic fever syndromes, mevalonate kinase deficiency (MKD) is the sole in which the phenotype did not directly associate with a deficiency of these proteins, but with a metabolic defect of the mevalonate pathway, highlighting the importance of this metabolic pathway in the inflammation control. Noteworthy, drugs acting on this pathway can greatly influence the inflammatory response. The modulation of inflammation by mevalonate pathway is of interest, since it may involve mechanisms not directly referable to inflammasomes. MKD provides a model to study these mechanisms and possibly to develop new classes of anti-inflammatory drugs.</p>},
	keywords = {Animals, Anti-Inflammatory Agents, Apoptosis, Cytokines, Drug Design, Hereditary Autoinflammatory Diseases, Humans, Inflammasomes, Inflammation, Mevalonate Kinase Deficiency, Mevalonic Acid},
	issn = {1873-4286},
	author = {Marcuzzi, Annalisa and Crovella, Sergio and Monasta, Lorenzo and Vecchi Brumatti, Liza and Gattorno, Marco and Frenkel, Joost}
}
